Fig. 2: Kaplan-Meier of time to next treatment. | Leukemia

Fig. 2: Kaplan-Meier of time to next treatment.

From: Clinical and transcriptomic characterization of patients with chronic lymphocytic leukemia harboring t(14;19): an ERIC study

Fig. 2

The Kaplan-Meier curves of time to the next treatment of patients treated with t(14;19) (tCLL) and other CLL without t(14;19) (oCLL) who received (A) fludarabine-cyclophosphamide-rituximab (FCR) / bendamustine-rituximab (BR) (n = 32 and n = 107, respectively), B venetoclax-based therapy (n = 6 and n = 39) and C BTK inhibitor (n = 14 and n = 180) as frontline therapy.

Back to article page